Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Second Quarter 2018 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.
NCIT TCON

3
TCON / TRACON Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
tcon-10q_20180630.htm UNITED STATES
TCON

3
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
tcon-8k_20180808.htm
TCON

8
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-10 sec.gov
tcon-8k_20180710.htm
TCON

14
TCON / TRACON Pharmaceuticals, Inc. null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S(P M,#@O3R [email protected],C
TCON

14
TCON / TRACON Pharmaceuticals, Inc. null

2018-06-24 sec.gov
tcon-corresp.htm TRACON Pharmaceuticals, Inc.
TCON

22
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-15 sec.gov
tcon-8k_20180613.htm
TCON

164
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

2018-06-15 seekingalpha
Wright Medical Group N.V. (WMGI) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF-BB) and a blend of Type I collagen and Beta tricalcium phosphate. The combination is used as a safe and effective alternative to autograft for use in hindfoot and ankle fusion in an easy to use flowable formulation.
SGEN REGN CUTR K RVVTF SCPH PULM AGN MRK CRBP CAH CLSD TCON RVV

16
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-13 sec.gov
tcon-8k_20180613.htm
TCON

15
TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

2018-05-31 globenewswire
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY.
TCON

14
TRACON Pharmaceuticals Reports Granting of Inducement Award

2018-05-31 globenewswire
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has issued an inducement award to a new executive employee.
TCON

90
Reader Inquiry: What's The Current Outlook For Tracon Pharmaceuticals?

2018-05-29 seekingalpha
The main value driver, in my eyes, continues to be data from the phase 2b TRAXAR study.
MRTX ARQL TCON

25
TCON / TRACON Pharmaceuticals, Inc. 424B3 (Prospectus)

2018-05-21 sec.gov
tcon-424b3.htm Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-224809
TCON

18
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-21 sec.gov
tcon-8k_20180517.htm
TCON

20
TCON / TRACON Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-10 sec.gov
tcon-10q_20180331.htm UNITED STATES
TCON

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 89237H100